Sanofi resumes growth in Q4 of 2013

French multinational pharmaceutical company headquartered in Paris posted group sales increased 6.5 per cent in Q4 of 2014, with emerging markets recording a double digit increase of 10.4 per cent.

2014-02-10 12:21:40

Commenting on the group performance in Q4 2013, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, "Sanofi growth profile emerged in Q4 2013 with total sales growing 6.5 per cent at CER and growth platforms, which represented 72.9% of sales, increasing 10.0% at CER. Furthermore, new product launches are underway or imminent in most of Sanofi core businesses and several high potential R&D projects progressed in 2013."

The group sales increased 6.5 percent in Q4 2013, while in 2013, total sales were stable (-0.5 per cent) at EUR 32.951 million, a company release stated. The growth platforms increased 10.0 per cent in Q4 2013. In 2013, sales from growth platforms reached €23,905 million (+6.6 per cent) and accounted for 72.5 percent of total sales.

In Q4 2013, emerging markets sales recorded double digit growth (+10.4 per cent). In 2013, emerging markets sales were EUR 10,957 million, an increase of 4.4 per cent (+7.1 per cent excluding Brazil generics). Diabetes sales were up 19.0 per cent in Q4 2013. Diabetes recorded strong double digit growth (+18.7 per cent) to EUR 6,568 million in 2013 driven by the performance of Lantus medicine (+20.0 per cent to EUR 5,715 million).

Vaccines sales were stable in Q4 2013 as supply improved for Pentacel and Adacel in the U.S. from mid-October. In 2013, vaccines sales were stable at EUR 3,716 million as record flu vaccines sales offset U.S. supply constraints on Pentacel and Adacel medicine brands. CHC sales were up 6.1 per cent in Q4 2013 while sales of consumer healthcare exceeded EUR 3 billion in 2013, an increase of +5.2 per cent.

Also, the company stated that animal health sales were down 6.3 percent in Q4 2013. Sales of animal health decreased 5.3 per cent to EUR 1,985 million in 2013 reflecting increased competition to Frontline. Broadline, a product created for the fight against internal and external parasites for cats, was approved in the EU in December.